Metabolic Tumor Volume Predicts Disease Progression and Survival in Patients with Squamous Cell Carcinoma of the Anal Canal
Authors:
- Albert C. KoongAKAlbert C. Koong
- Billy W. LooBLBilly W. Loo
- 12 December 2012
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 54 (1) , 27-32
Abstract
PET imaging has become a useful diagnostic tool in patients with anal cancer. We evaluated the prognostic value of metabolic tumor volume (MTV) in patients with anal cancer treated with definitive chemoradiotherapy. Methods: Patients with anal cancer who underwent PET imaging for pretreatment staging or radiation therapy planning from 2003 to 2011 were included. PET parameters included MTV and maximum standardized uptake value (SUVmax). Total MTV (MTV-T) was defined as the sum of the volumes above a standardized uptake value 50% of the SUVmax within the primary tumor and involved nodes. Kaplan–Meier and Cox regression models were used to test for associations between metabolic or clinical endpoints and overall survival (OS), progression-free survival (PFS), and event-free survival (EFS). Results: Thirty-nine patients were included. Median follow-up for the cohort was 22 mo. Overall, 6 patients died and 9 patients had disease progression. The 2-y OS, PFS, and EFS for the entire cohort were 88%, 74%, and 69%, respectively. Higher MTV-T was associated with worse OS (P = 0.04), PFS (P = 0.004), and EFS (P = 0.002) on univariate analysis. Patients with an MTV greater than 26 cm3 had worse PFS than did those with an MTV of 26 cm3 or less (33% vs. 82%, P = 0.003). SUVmax was not prognostic for any outcome. Higher T classification (T3/T4 vs. T1/T2) was associated with worse PFS and EFS. When adjusting for T classification, MTV-T remained a significant predictor for PFS (P = 0.01) and EFS (P = 0.02). Conclusion: MTV-T yields prognostic information on PFS and EFS beyond that of established prognostic factors in patients with anal cancer.Keywords
This publication has 23 references indexed in Scilit:
- Positron Emission Tomography/Computed Tomography in the Staging and Treatment of Anal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Contrast-Enhanced [18F]fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Staging and Radiotherapy Planning in Patients With Anal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Prognostic factors derived from a prospective database dictate clinical biology of anal cancerCancer, 2010
- Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosisRadiotherapy and Oncology, 2010
- Assessing the impact of FDG-PET in the management of anal cancerRadiotherapy and Oncology, 2008
- Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal CanalJAMA, 2008
- FDG-PET/CT in the evaluation of anal carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.Journal of Clinical Oncology, 1997
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycinThe Lancet, 1996
- Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.Journal of Clinical Oncology, 1996